Sign up to get each new magazine issue delivered to your inbox

March 2023

In our next issue, we will explore new advances in pharma R&D, from drugs to delay type 1 diabetes to Alzheimer’s disease vaccines.. The March issue will also feature the latest trends in decentralised clinical trial (DCT) operations and pharma manufacturing.

EDITORIAL

Editor | Manasi Vaidya

Writers | Fiona Barry, Urtė Fultinavičiūtė, Irena Maragkou, Akosua Mireku, Manasi Vaidya, Adam Zamecnik

Magazine Designer | Will Ingham
Graphic Designers | Anett Arc, Noemi Balint, Martina Labaiova

Publisher | Susanne Hauner

Advertising

Sales Manager | Tom McCormick
+44 207 8669440

Cover image: Composite. Credit: PremiumArt, Ardea-studio and Will Ingham

Pharma Technology Focus is powered by H5mag

Read past issues of Pharma Technology Focus HERE

Copyright 2023 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | CRISPR gene therapies cut through in 2023Go to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: TripletreeGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: HOF SonderanlagenbauGo to article: Owen Mumford Company InsightGo to article: Owen Mumford AidaptusGo to article: CommentGo to article: High hopes for mRNA anti-cancer vaccines with early successesGo to article: Cell therapies might revolutionise treatment for multiple sclerosis patientsGo to article: Downturn for top biopharma companies as Covid-19 vaccine demand falls in Q3Go to article: Inflation threatens supply of life-saving generics to EuropeGo to article: Data is the key to a safer and more controlled pharmaceutical cold-chainGo to article: Molnar-Institute Company Insight Go to article: Molnar-InstituteGo to article: In DepthGo to article: CRISPR gene therapies: Is 2023 a milestone year in the making?Go to article: Tracking the ups and downs of pharma dealsGo to article: Regulation starts to catch up with AI in pharmaGo to article: Next on trial diversity: Embracing participants with cognitive impairmentGo to article: Digital twins: The next frontier to ease clinical trial conductGo to article: CMO Moves: Regulatory catalysts for therapy manufacturing -JanuaryGo to article: EventsGo to article: Next issue